http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View More Recent Stories
-
Veracyte Announces Clinical Validation Data Demonstrating Envisia™ Genomic Classifier's Performance in Improving Idiopathic Pulmonary Fibrosis Diagnosis Presented at ATS 2017
-
Veracyte (VCYT) Reports Anthem Coverage for Afirma GEC for Use in Thyroid Cancer Diagnosis
-
Veracyte Announces Anthem Coverage for the Afirma® Gene Expression Classifier for Use in Thyroid Cancer Diagnosis
-
Data Demonstrating Cost-Effectiveness of Veracyte's Percepta® Bronchial Genomic Classifier Published in "Journal of Thoracic Oncology"
-
Veracyte Announces Six Studies Highlighting Value of Company's Genomic Classifiers in Lung Cancer and Idiopathic Pulmonary Fibrosis To Be Presented at ATS 2017
-
Data Presented at AACE 2017 Annual Meeting Demonstrate Long-Term Clinical Utility Of Veracyte's Afirma® Gene Expression Classifier in Thyroid Cancer Diagnosis
-
Veracyte Announces Pivotal Clinical Validation Data for Next-Generation Afirma® Test To Help More Patients Avoid Unnecessary Surgery in Thyroid Cancer Diagnosis
-
Veracyte Announces First Quarter 2017 Financial Results
-
Veracyte Announces Multiple Studies Demonstrating Powerful Results from Afirma® Classifiers To Be Presented at the AACE 2017 Annual Meeting
-
Veracyte to Host Conference Call and Webcast to Discuss First Quarter 2017 Financial Results on Wednesday, May 3, 2017
-
Veracyte (VCYT) Presents Positive Data at ENDO 2017 Supporting Afirma® Gene Expression Classifier In Thyroid Cancer Diagnosis
-
Multiple Studies Presented at ENDO 2017 Support Use of Veracyte's Afirma® Gene Expression Classifier In Thyroid Cancer Diagnosis
-
Veracyte (VCYT) Says Multiple Studies Supporting Clinical Utility of Afirma Gene Expression Classifier to Be Presented at ENDO
-
Veracyte Announces that Multiple Studies Supporting Clinical Utility of Its Afirma® Gene Expression Classifier To Be Presented at ENDO 2017
-
Veracyte Announces Fourth Quarter and Full-Year 2016 Financial Results, Provides 2017 Financial Outlook
-
Veracyte Announces Executive Promotions
-
Veracyte (VCYT) Announces Publication of Data Showing Potential for Non-Invasive Nasal Test to Improve Lung Cancer Diagnosis
-
Veracyte Announces Publication of Data Demonstrating Potential for Non-Invasive Nasal Test to Improve Lung Cancer Diagnosis
-
Veracyte Announces Ten New Blues Plan Coverage Policies for Its Afirma® Gene Expression Classifier for Use in Thyroid Cancer Diagnosis
-
Veracyte to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2016 Financial Results on Wednesday, March 1, 2017
-
Veracyte (VCYT) Enters Agreement with Quest Diagnostics (DGX) to Expand Patient Access to GEC
-
Veracyte to Expand Patient Access to the Afirma® Gene Expression Classifier In Thyroid Cancer Diagnosis Through Agreement with Quest Diagnostics
-
Veracyte (VCYT) Announces Final Medicare Coverage Policies for Percepta
-
Veracyte Announces Final Medicare Coverage Policies for Percepta® Bronchial Genomic Classifier
-
Veracyte to Present at LEERINK Partners 6th Annual Global Healthcare Conference

